Logo image of OSTX

OS THERAPIES INC (OSTX) Stock Fundamental Analysis

NYSEARCA:OSTX - American Stock Exchange - US68764Y2072 - Common Stock

2.95  -1.17 (-28.4%)

After market: 3.0101 +0.06 (+2.04%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to OSTX. OSTX was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of OSTX have multiple concerns. OSTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

OSTX had negative earnings in the past year.
OSTX Yearly Net Income VS EBIT VS OCF VS FCFOSTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -2M -4M -6M

1.2 Ratios

OSTX has a Return On Assets of -375.20%. This is amonst the worse of the industry: OSTX underperforms 96.46% of its industry peers.
Industry RankSector Rank
ROA -375.2%
ROE N/A
ROIC N/A
ROA(3y)-1516.92%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OSTX Yearly ROA, ROE, ROICOSTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OSTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OSTX Yearly Profit, Operating, Gross MarginsOSTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

OSTX has less shares outstanding than it did 1 year ago.
The debt/assets ratio for OSTX has been reduced compared to a year ago.
OSTX Yearly Shares OutstandingOSTX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M 20M
OSTX Yearly Total Debt VS Total AssetsOSTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 5M 10M

2.2 Solvency

OSTX has an Altman-Z score of -14.26. This is a bad value and indicates that OSTX is not financially healthy and even has some risk of bankruptcy.
OSTX has a Altman-Z score of -14.26. This is amonst the worse of the industry: OSTX underperforms 81.42% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.26
ROIC/WACCN/A
WACCN/A
OSTX Yearly LT Debt VS Equity VS FCFOSTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 10M -10M -20M

2.3 Liquidity

OSTX has a Current Ratio of 0.76. This is a bad value and indicates that OSTX is not financially healthy enough and could expect problems in meeting its short term obligations.
OSTX has a worse Current ratio (0.76) than 91.33% of its industry peers.
OSTX has a Quick Ratio of 0.76. This is a bad value and indicates that OSTX is not financially healthy enough and could expect problems in meeting its short term obligations.
OSTX's Quick ratio of 0.76 is on the low side compared to the rest of the industry. OSTX is outperformed by 91.33% of its industry peers.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.76
OSTX Yearly Current Assets VS Current LiabilitesOSTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

OSTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -40.49%.
EPS 1Y (TTM)-40.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 36.97% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-200.83%
EPS Next 2Y142.82%
EPS Next 3Y36.97%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OSTX Yearly Revenue VS EstimatesOSTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M 50M
OSTX Yearly EPS VS EstimatesOSTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 0.5 -0.5 1 -1

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OSTX. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 1.97, which indicates a rather cheap valuation of OSTX.
OSTX's Price/Forward Earnings ratio is rather cheap when compared to the industry. OSTX is cheaper than 99.29% of the companies in the same industry.
OSTX is valuated cheaply when we compare the Price/Forward Earnings ratio to 24.11, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 1.97
OSTX Price Earnings VS Forward Price EarningsOSTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OSTX Per share dataOSTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

OSTX's earnings are expected to grow with 36.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y142.82%
EPS Next 3Y36.97%

More info and screens

0

5. Dividend

5.1 Amount

OSTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OS THERAPIES INC

NYSEARCA:OSTX (1/17/2025, 8:19:31 PM)

After market: 3.0101 +0.06 (+2.04%)

2.95

-1.17 (-28.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-15 2024-11-15/bmo
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner Change0%
Ins Owners24.84%
Ins Owner Change0%
Market Cap62.66M
Analysts82.22
Price Target12.92 (337.97%)
Short Float %0.32%
Short Ratio0.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-15.56%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-62.64%
Revenue NY rev (3m)-62.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.97
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.36
EYN/A
EPS(NY)1.5
Fwd EY50.83%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -375.2%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1516.92%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.76
Quick Ratio 0.76
Altman-Z -14.26
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-200.83%
EPS Next 2Y142.82%
EPS Next 3Y36.97%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y20.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.71%
OCF growth 3YN/A
OCF growth 5YN/A